Investigators Choice clinical trials

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

This study looks at a new drug, tebentafusp, for people with advanced melanoma that has already been treated. We want to see if tebentafusp, alone or with another drug called pembrolizumab, works better and is safer than standard treatments or best supportive care.